|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
|
DE69839355T2
(de)
|
1997-07-29 |
2009-06-04 |
Alcon Laboratories, Inc., Fort Worth |
Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
|
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
|
EP1654002B2
(en)
|
2003-08-07 |
2014-01-29 |
Allergan, Inc. |
Compositions for delivery of therapeutics into the eyes
|
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
|
US20190055192A1
(en)
|
2004-06-07 |
2019-02-21 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
|
PT1812440E
(pt)
|
2004-11-04 |
2011-01-25 |
Vertex Pharma |
Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
|
|
WO2006088972A2
(en)
|
2005-02-16 |
2006-08-24 |
The General Hospital Corporation |
Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
|
|
CA2631312A1
(en)
|
2005-11-29 |
2007-06-07 |
Nevada Cancer Institute |
Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)
|
|
JP5638961B2
(ja)
|
2008-03-13 |
2014-12-10 |
ザ ジェネラル ホスピタル コーポレイション |
Ｂｍｐシグナル伝達経路のインヒビター
|
|
CN105503882B
(zh)
*
|
2010-03-03 |
2019-07-05 |
艾尼纳制药公司 |
制备s1p1受体调节剂及其晶体形式的方法
|
|
US20120115878A1
(en)
|
2010-11-10 |
2012-05-10 |
John Vincent Calienni |
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
|
|
EP2964651A4
(en)
|
2013-03-04 |
2016-11-30 |
Brigham & Womens Hospital |
BMP HEMMER AND METHOD OF USE THEREOF
|
|
WO2014160203A2
(en)
*
|
2013-03-14 |
2014-10-02 |
The Brigham And Women's Hospital, Inc. |
Bmp inhibitors and methods of use thereof
|
|
WO2014152006A2
(en)
|
2013-03-15 |
2014-09-25 |
Intrinsic Lifesciences, Llc |
Anti-hepcidin antibodies and uses thereof
|
|
US10513521B2
(en)
|
2014-07-15 |
2019-12-24 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for inhibiting BMP
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
CN109311889B
(zh)
|
2016-04-15 |
2021-11-16 |
缆图药品公司 |
激活素受体样激酶抑制剂
|
|
EP3615538B1
(en)
|
2017-04-27 |
2024-02-07 |
The Brigham and Women's Hospital, Inc. |
Novel alk2 inhibitors and methods for inhibiting bmp signaling
|
|
AR112027A1
(es)
|
2017-06-15 |
2019-09-11 |
Biocryst Pharm Inc |
Inhibidores de alk 2 quinasa que contienen imidazol
|
|
EP3697786B1
(en)
|
2017-10-18 |
2022-08-31 |
Blueprint Medicines Corporation |
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
|
|
CU20200035A7
(es)
|
2017-11-24 |
2021-03-11 |
Novartis Ag |
Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2
|
|
WO2020068729A1
(en)
|
2018-09-25 |
2020-04-02 |
Incyte Corporation |
Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
|
|
CN113366019B
(zh)
|
2018-10-23 |
2024-08-27 |
科乐斯疗法公司 |
Alk2抗体及其使用方法
|
|
EP3870181B1
(en)
|
2018-10-26 |
2024-08-14 |
Keros Therapeutics, Inc. |
Crystal forms of an alk2 inhibitor
|
|
TWI870440B
(zh)
|
2019-08-13 |
2025-01-21 |
美商纜圖藥品公司 |
活化素受體樣激酶抑制劑之鹽及晶體形式
|
|
ES3014839T3
(en)
|
2019-10-02 |
2025-04-25 |
Blueprint Medicines Corp |
Process for preparing an activin receptor-like kinase inhibitor
|
|
JP7717065B2
(ja)
|
2019-11-22 |
2025-08-01 |
インサイト コーポレーション |
Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
|
|
US12508262B2
(en)
|
2020-04-30 |
2025-12-30 |
Keros Therapeutics, Inc. |
Methods of using ALK2 inhibitors
|
|
WO2022098812A1
(en)
|
2020-11-04 |
2022-05-12 |
Keros Therapeutics, Inc. |
Methods of treating iron overload
|
|
WO2022098821A1
(en)
|
2020-11-04 |
2022-05-12 |
Keros Therapeutics, Inc. |
Methods of treating lymphopenia
|
|
WO2022099166A1
(en)
|
2020-11-09 |
2022-05-12 |
Keros Therapeutics, Inc. |
Methods of treating cardiovascular-related disease
|
|
US20250034148A1
(en)
|
2021-11-02 |
2025-01-30 |
Keros Therapeutics, Inc. |
Methods of using alk2 inhibitors
|